MA34098B1 - Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs - Google Patents

Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs

Info

Publication number
MA34098B1
MA34098B1 MA35265A MA35265A MA34098B1 MA 34098 B1 MA34098 B1 MA 34098B1 MA 35265 A MA35265 A MA 35265A MA 35265 A MA35265 A MA 35265A MA 34098 B1 MA34098 B1 MA 34098B1
Authority
MA
Morocco
Prior art keywords
tumors
treatment
cdk inhibitors
new pan
pan
Prior art date
Application number
MA35265A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Ulrich Lücking
Gerhard Siemeister
Antje Margret Wengner
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34098B1 publication Critical patent/MA34098B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA35265A 2010-04-01 2011-03-28 Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs MA34098B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010014426A DE102010014426A1 (de) 2010-04-01 2010-04-01 Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
PCT/EP2011/054733 WO2011120922A1 (de) 2010-04-01 2011-03-28 Verwendung neuer pan-cdk-inhibitoren zur behandlung von tumoren

Publications (1)

Publication Number Publication Date
MA34098B1 true MA34098B1 (fr) 2013-03-05

Family

ID=43858236

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35265A MA34098B1 (fr) 2010-04-01 2011-03-28 Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs

Country Status (21)

Country Link
US (1) US20130210846A1 (enExample)
EP (1) EP2552450A1 (enExample)
JP (1) JP5816259B2 (enExample)
KR (1) KR20130014678A (enExample)
CN (1) CN102834100A (enExample)
AU (1) AU2011234654B2 (enExample)
BR (1) BR112012024422A2 (enExample)
CA (1) CA2794996A1 (enExample)
CL (1) CL2012002753A1 (enExample)
CR (1) CR20120502A (enExample)
DE (1) DE102010014426A1 (enExample)
DO (1) DOP2012000260A (enExample)
EC (1) ECSP12012198A (enExample)
MA (1) MA34098B1 (enExample)
MX (1) MX337722B (enExample)
NZ (1) NZ602710A (enExample)
PH (1) PH12012501945A1 (enExample)
SG (2) SG183925A1 (enExample)
TN (1) TN2012000469A1 (enExample)
UA (1) UA108494C2 (enExample)
WO (1) WO2011120922A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1204294A1 (en) * 2012-03-21 2015-11-13 拜耳知识产权有限责任公司 Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
AP2015008753A0 (en) * 2013-03-07 2015-09-30 Bayer Pharma AG Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]-oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours
KR20220123335A (ko) * 2013-03-13 2022-09-06 온코슈틱스 인코포레이티드 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
WO2014202583A1 (en) * 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
WO2015071231A1 (de) * 2013-11-14 2015-05-21 Bayer Pharma Aktiengesellschaft Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法
CA3202990A1 (en) * 2020-11-27 2022-06-02 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Aminoheteroaryl kinase inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
AU744986B2 (en) 1997-07-12 2002-03-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
AU2002312933B2 (en) 2001-05-29 2007-12-06 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP1878726A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2179991A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
JP2013523680A (ja) 2013-06-17
CA2794996A1 (en) 2011-10-06
CN102834100A (zh) 2012-12-19
TN2012000469A1 (en) 2014-01-30
AU2011234654B2 (en) 2015-08-06
SG183925A1 (en) 2012-10-30
MX337722B (es) 2016-03-16
CR20120502A (es) 2012-11-20
UA108494C2 (uk) 2015-05-12
US20130210846A1 (en) 2013-08-15
DE102010014426A1 (de) 2011-10-06
MX2012011427A (es) 2013-03-05
BR112012024422A2 (pt) 2016-05-31
JP5816259B2 (ja) 2015-11-18
CL2012002753A1 (es) 2013-01-18
KR20130014678A (ko) 2013-02-08
AU2011234654A1 (en) 2012-10-25
ECSP12012198A (es) 2012-10-30
SG10201502566SA (en) 2015-05-28
WO2011120922A1 (de) 2011-10-06
EP2552450A1 (de) 2013-02-06
DOP2012000260A (es) 2013-03-31
PH12012501945A1 (en) 2017-08-09
NZ602710A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
JOP20180104A1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
PH12017502141A1 (en) Compounds and their methods of use
JOP20180103A1 (ar) مركب صيدلاني
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201590748A1 (ru) Противовирусные соединения против rsv
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY34472A (es) Derivados modificados de 4-fenil-piridina
MX393993B (es) Inhibidores de bromodominio
UY34145A (es) Compuestos inhibidores de metaloenzimas
EA201300730A1 (ru) Производные индазолилтриазола
GEP201706688B (en) Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
UY34300A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
EA201790418A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
UY33930A (es) Inhibidores novedosos de quinasas
EA201690844A1 (ru) Ингибиторы gsk-3
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
MX349548B (es) Compuestos de tienopirimidina.
EA201170997A1 (ru) Производные индола в качестве противораковых агентов